$17.94
arrow_drop_up4.12%Key Stats | |
---|---|
Open | $17.82 |
Prev. Close | $17.23 |
EPS | -3.06 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 17.25 | 18.07 |
52 Week Range | 7.64 | 30.18 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -3.06 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer